Argentina
Industry
BMI View: We expect multinationals to continue to reduce operations in Argentina due to the country's gloomy economic outlook. However, this trend can provide opportunities for local...
2013-02-07Industry
BMI View: The approval of Kombiglyze XR in Argentina indicates that there are still revenue-generating opportunities for innovative drugmakers who can meet epidemiological needs in...
2013-02-06Industry
BMI View: Argentina's pharmaceutical market will become increasingly unattractive to drug companies due to the country's quick deteriorating economy. The country's double-digit drug...
2012-09-06Industry
BMI View: Argentina's new government healthcare programme will improve the social welfare of women and children who previously lacked efficient access to public healthcare. It will...
2012-08-09Industry
BMI View: China is in a unique position in that it can ignore Argentina's increasingly unsustainable macroeconomic policy trajectory and focus on tapping the long-term potential in...
2012-07-12Industry
BMI View: The benefit of fetal mesenchymal stem cells (MSC) preservation is theoretical and overstated. However, the growing healthcare markets of Brazil, Mexico, Argentina and Colombia...
2012-06-20Industry
BMI View: We previously highlighted that Spanish pharmaceutical companies have increased their Latin American presence due to their deteriorating domestic market.[1] However, compared...
2012-06-18Industry
BMI View: Corporación Farmacéutica Recalcine (CFR)'s foreign expansion strategy is likely to bring significant commercial returns. Mergers and acquisitions (M&A) facilitate market...
2012-03-27
